Evaluation of analgesic uptake, pain intensity, and quality-of-life changes after half-body irradiation of patients with bone metastases.
Material and Methods
Ninety-five patients (97 irradiations) were treated with single half-body irradiation fraction (3–8 Gy). Thirty-three patients had upper-half-body irradiation, 55 lower-half-body irradiation and 9 middle-half-body irradiation. The patients were examined on the day of irradiation, 2 and 4 weeks later, and then once a month. The intake of analgesics, pain level (from 0 to 10), and the quality of life (EORTC QLQ-C30) were evaluated. The fluctuations of pain levels and the particular scaling values of QLQ-C30 during a one-year period were analyzed (Kendall t correlation).
Results
Over the course of 5 months, the incidence of patients using strong opioids decreased from 43.8% to 33.3%, and the incidence of patients who did not need to resort to analgesics increased from 6.7% to 25%. The mean pain level decreased from 6.1 points (half-body irradiation) to 3.1 points 2 weeks later. An inverse correlation between pain level readings and time was statistically significant. An increase was observed in the values of the five functional scales as reflected on the EORTC QLQ-C30 questionnaire (four of which correlated significantly with the observation time). A similar situation prevailed with respect to global health status. A decrease was observed in most of the values on the symptoms scales; 6 saw a significant decrease, in correlation with the follow-up. Correlations were also found between pain intensity and functionality, and between symptoms scales readings and global health status.
Conclusions
Half-body irradiation of cancer patients suffering from painful multiple bone dissemination is an effective and simple treatment modality that affords significant quality-of-life improvement and pain relief, thus allowing for a reduction in the use of strong analgesics.
RescheI., ChatalJ.F., PeckingA., EllP., DuchesneG., RubensR., FogelmanI., HoustonS., FauserA., FischerM., WilkinsD.: A dose-controlled study of 153 Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.Eur J Cancer, 33: 1583–1591, 1997.
2.
SerafiniA.N., HoustonS.J., RescheI., QuickD.P., GrundF.M., EllP.J., BertrandA., AhmannF.R., OrihuelaE., ReidR.H., LerskiR.A., ColierB.D., McKillopJ.H., PurnellG.L., PeckingA.P., ThomasF.D., HarrisonK.A.: Palliation for pain associated with metastatic bone cancer using Samarium 153 lexidronam: a double blind placebo-controlled clinical trial.J Clin Oncol, 16: 1574–1581, 1998.
3.
SilbersteinE.B., EugeneL., SaengerS.R.: Painful osteoblastic metastases: the role of nuclear medicine.Oncology, 15: 157–163, 2001.
4.
BosS.D.: An overview of current clinical experiences with strontium-89 (Metastron).Prostate, (Suppl 5): 23–26, 1994.
5.
BremerM., RadesD., BlachM., KrenkelM., KarstensJ.H.: Effectiveness of hypofractionated radiotherapy in painful bone metastases. Two prospective studies with 1×4 Gy and 4×4Gy.Strahlenther Onkol, 175: 382–386, 1999.
6.
Ben-JosefE., ShamsaF., WilliamsA.O., PorterA.T.: Radiotherapeutic management of osseus metastases: a survey of current patterns of care.Int J Radiat Oncol Biol Phys, 40: 915–921, 1998.
7.
ChowE., DanjouxC., WongR., SzumacherE., FranssenE., FungK., FinklesteinJ., AnderssonL., ConnollyR.: Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists.Radiother Oncol, 56: 305–314, 2000.
8.
DearnaleyD.P., BaylyR.J., A'HernR.P., GaddJ., ZivanovicM.M., LevingtonV.J.: Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89.Clin Oncol, 4: 101–107, 1992.
9.
KorbL.: Radiotherapy for the palliation of prostate cancer.Semin Surg Oncol, 18: 75–79, 2000.
10.
MiszczykL., GaborekA., WydmańskiJ.: The evaluation of life quality after HBI performed due to multiple skeletal dissemination.Ortop Traumat Rehab, 5: 215–218, 2003.
11.
MiszczykL., GaborekA., WydmańskiJ.: An effectiveness evaluation of hemibody irradiation as a palliative treatment of patients with multiple, painful bone dissemination.Wspólcz Onkol, 9: 218–222, 2005.
12.
MiszczykL., SăsiadekW.: Evaluation of hemibody irradiation effectiveness as palliation of patients with multiple bone metastases.Przegl Lek, 58: 431–434, 2001.
PoulterC.A., CosmatosD., RubinP., UrtasunR., CooperJ.S., KuskeR.R., HornbackN., CouglinC., WeigensbergI., RotmanM.: A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases.Int J Radiat Oncol Biol Phys, 23: 207–214, 1992.
16.
SalazarO., Da MottaN.W., BridgmanS.M., CardigesN.M., SlawsonR.G.: Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose.Int J Radiat Oncol Biol Phys, 36: 49–60, 1996.
17.
SalazarO., RubinP., HendricksonF.R., KomakiR., PoulterC., NewallJ., AsbellS.O., MohiuddinM., Van EssJ.: Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors.Cancer, 58: 29–36, 1986.
18.
SalazarO., SandhuT., Da MottaN.W., Perez EscutiaM.A., Lanzos-GonzalesE., Mouelle-SoneA., MoscolA., ZahariaM., ZamanS.: Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the International Atomic Energy Agency (IAEA)Int J Radiat Oncol Biol Phys, 50: 765–775, 2001.
19.
SalazarO., ScarantinoC.W.: Theorethical and practical uses of elective systemic (half-body) irradiation after 20 years of experimental designs.Int J Radiat Oncol Biol Phys, 39: 907–913, 1997.
20.
SkolyszewskiJ., Sas-KorczyńskaB., KorzeniowskiS., ReinfussM.: The efficiency and tolerance of half-body irradiation (HBI) in patients with multiple metastases.Strahlenther Oncol, 177: 482–486, 2001.
21.
DuchesneG.M., HarmerC.L.: Hemibody irradiation in lymphomas and related malignanciesInt J Radiat Oncol Biol Phys, 11: 2003–2006, 1985.
22.
ScarantinoC.W., GrevenK.M., BussD.H.: Single high dose large field irradiation in drug resistant non-Hodgkin's lymphoma.Int J Radiat Oncol Biol Phys, 14: 1001–1005, 1988.
23.
PlesnicarA., JerebB., Zalatel-KrageljL.: Half-body irradiation in the treatment of multiple myeloma: a report of nine cases.Tumori, 82: 588–591, 1996.
24.
QuasimM.M.: Techniques and results of half body irradiation (HBI) in metastatic carcinomas and myelomas.Clin Oncol, 5: 65–68, 1979.
TomiskaM., TomiskovaM., SaljkaF., AdamZ., VorlicekJ.: Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.Neoplasma, 50: 227–233, 2003.
27.
CleelandC.S., RyanK.M.: Pain assessment: global use of the Brief Pain Inventory.Ann Acad Med Singapore, 23: 129–138, 1994.
28.
MiszczykL., FicekK., TrelaK., SpindelJ.: The efficacy of radiotherapy for vertebral hemangiomas.Neoplasma, 48: 82–84, 2001.
29.
JandaM., GerstnerM., ObermairA., FuerstA., WachterS., DieckmannK., PotterR.: Quality of life changes during conformal radiation therapy for prostate carcinoma.Cancer, 89: 1322–1328, 2000.
30.
WojtowiczJ.G., WierzbickaM., SzyfterW.: Usefulness of questionnaire EORTC QLQ-C30 and EORTC QLQ-H&N35 in assessment of quality of life before surgical treatment in patients with head and neck cancer.Otolaryngol Pol, 55: 627–634, 2001.
31.
KesslerP.A., Bloch-BirkholzA., LeherA., NeukamF.W., WiltfangJ.: Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study.Radiother Oncol, 70: 275–282, 2004.
32.
WierzbickaM., KusnierkiewiczM., WojtowiczJ.G., MauneS., SzyfterW.: The quality of life in head and neck cancer patients – description of randomised examination formula based on standarised questionnaires EORTC QLQ-C30, EORTC QLQ-H&N35 and Kiel Questionnaire.Otolaryngol Pol, 55: 287–292, 2001.
33.
GrallaR.J.: Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.Oncologists, 9: 14–24, 2004.
34.
HagelinC.L., SeigerA., FurstC.J.: Quality of life in terminal care – with special reference to age, gender and marital status.Support Care Cancer, 14: 320–228, 2006.
35.
HomsM.Y.V., Essink-BotM.L., BorsboomGJJM, SteyerbergE.W., SiersemaP.D.: Quality of life after palliative treatment for oesophageal carcinoma: a prospective comparison between stent placement and single dose brachytherapy.Eur J Cancer, 40: 1862–1871, 2004.
36.
ParkS.M., ParkM.H., WonJ.H., LeeK.O., ChoeW.S., HeoD.S., KimS.Y., LeeK.S., YunY.H.: EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units.Support Care Cancer, 14: 329–333, 2006.
37.
EsbansenB.A., OsterlindK., RoerO., HallbergI.R.: Quality of life of elderly persons with newly diagnosed cancer.Eur J Cancer Care, 13: 443–453, 2004.
38.
ThomeB., HallbergI.R.: Quality of life in older people with cancer - a gender perspective.Eur J Cancer Care, 13: 454–463, 2004.
39.
AaronsonN.K., AhmedzaiS., BergmanB., BullingerM., CullA., DuezN.J., FilibertiA., FlechtnerH., FleihsmanS.B., de HaesJCJM, KaasaS., KleeM.C., OsobaD., RazaviD., RofeP.B., SchraubS., SneuwK.C.A., SullivanM., TakedaR.: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst, 85: 365–376, 1993.
40.
FayersP.M., AaronsonN.K., BjordalK., GroenvoldM., CurranD., Bottomley A on behalf of EORTC Quality of Life Group: The EORTC QLQ-C30 Scoring Manual (3rd edition), European Organisation for Research and Treatment of Cancer, Brussels, 2001.
